HC Wainwright Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $100.00

BridgeBio Pharma (NASDAQ:BBIO) had its price objective lifted by HC Wainwright from $90.00 to $100.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 35.26% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. Truist Financial boosted their price target on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Cantor Fitzgerald increased their price objective on BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Finally, Oppenheimer increased their price target on shares of BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.05.

BridgeBio Pharma Stock Down 2.5%

NASDAQ BBIO opened at $73.93 on Tuesday. The firm’s 50 day moving average is $75.73 and its 200-day moving average is $63.79. The company has a market capitalization of $14.25 billion, a PE ratio of -17.69 and a beta of 1.13. BridgeBio Pharma has a 12-month low of $28.33 and a 12-month high of $84.94.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares in the company, valued at $9,675,855.22. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 176,121 shares of company stock valued at $13,009,631 in the last 90 days. Insiders own 18.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BBIO. Corient Private Wealth LLC bought a new position in shares of BridgeBio Pharma in the second quarter worth $643,000. WINTON GROUP Ltd acquired a new stake in BridgeBio Pharma during the second quarter worth about $3,856,000. Principal Financial Group Inc. increased its holdings in BridgeBio Pharma by 23.0% in the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock valued at $65,829,000 after buying an additional 236,885 shares during the period. Federated Hermes Inc. increased its holdings in BridgeBio Pharma by 53.0% in the 3rd quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after buying an additional 147,108 shares during the period. Finally, Bosun Asset Management LLC raised its position in shares of BridgeBio Pharma by 119.7% in the 2nd quarter. Bosun Asset Management LLC now owns 26,154 shares of the company’s stock valued at $1,129,000 after buying an additional 14,250 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.